Thank you for submitting your manuscript for consideration by The EMBO Journal. I would like to apologize for the fact that it has taken somewhat longer than usual to have it evaluated, but we have now finally received the reports from all three experts that had agreed to review it. As you will see, the referees acknowledge the potential importance of your newly identified interaction of BRCA2 and APRIN in genome integrity maintenance. Nevertheless, all referees raise a number of substantive points to be clarified before publication would appear warranted. While it would not for all of these points appear essential to address them exhaustively within the scope of the current submission (e.g. referee 3 point 3), two main issues will need to be further supported by experimental data: 1) the question whether APRIN forms or influences damage-induced foci, raised by referees 1 and 2; and 2) to provide more convincing HR repair efficiency assays as requested by referee 2, using a stably integrated HR reporter in at least some of the key experiments. In addition, I would also ask you to attend to the various more specific or technical concerns raised in the reports of referee 1 and 3, which should mostly be addressable in a straightforward manner and which in our opinion would greatly strengthen the manuscript and its appeal to a wide readership. Finally, please also be sure to carefully revise and proofread the manuscript on the editorial level, including the updating of incomplete citations in the reference list and the correction of inaccuracies such as the citation of a trypanosomal BRCA2 paper when discussing a fungal (Ustilago) ortholog BRCA2 on page 12. I also noted that the figure panels containing blots appear all very dark, and feel they might benefit from (moderate/conservative) contrast or brightness adjustments.
With these improvements and revisions, we should be able to consider a revised version of the manuscript further for publication. Please not however that it is our policy to allow only a single round of major revision, making it important to diligently and completely answer to all the points raised at this stage. We generally allow three months as standard revision time, and it is our policy that competing manuscripts published during this period will have no negative impact on our final assessment of your revised study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Should you foresee a problem in meeting this three-month deadline, please let us know in advance and we may be able to grant an extension.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html Should you have any further question regarding this decision or your revision, please do not hesitate to contact me. I look forward to your revision. This is a very elegant paper by the Ashworth and Lord groups. In this paper, they identified APRIN as a BRCA2 partner. Remarkably, APRIN is required for the nuclear localization of RAD51 and homologous recombination. APRIN associates with BRCA2 in early S-phase. Interestingly, APRIN expression can be correlated by the histological grade in breast cancer. Moreover, some mutations in BRCA2 in the APRIN-binding domain (166 amino acids, 15 variants tested) impaired homologous recombination. Overall, the experiments described here are well-controlled and convincing. Figure 2D -E. How can we explain that there is not a correlation between APRIN/BRCA2 interaction and HR (GFP positives cells) ? The S1069F mutant (which has almost lost all interaction between APRIN and BRCA2) has the same GFP level than A1109V that still interacts with APRIN.
It is not clear why the authors do not measure HR with the T1011R mutant, which is the most impaired mutant for interaction with APRIN.
It is not clear what is the explanation for the increase of GFP positive cells (using the N1101Y mutant). Figure 3A . Cell survival should be measured after aphidicolin and HU treatment to be in accordance with rest of the paper. Figure S3 . Some survival curves are not very convincing (T47D IR and MCF10A). It is not clear how siAPRIN and siCTL have a bigger effect than siBRCA2 (MCF10A and IR treatment (for 8 and 10 Gy)). Can this be explained by knockdown efficiency (proper western blots should be shown). Figure 4 . Does siRNA against APRIN has an effect on BRCA2 foci formation after DNA damage? Do BRCA2 or RAD51 colocalize with APRIN after DNA damage? Figure 4A . Do we know whether RAD51 foci formation decrease after aphidicolin or HU ? Also, RAD51 foci are not clearly visible. The authors should provide separate pictures for DAPI and RAD51 foci formation. Figure 4C . After siBRCA2 there is only 30-40% of decrease of HR (as measured by GFP positive cells). Nevertheless it is already known that BRCA2 knockdown abolish completely HR (GFP<10-20%). It is important to clarify this point. Can this be explained by knockdown efficiency (proper western blots should be shown).
Referee #2 (Remarks to the Author):
This m/s describes a new interaction between BRCA2 and the cohesin-associated protein, APRIN. This interaction was originally identified by studying proteins associated with a drosophila BRCA2 ortholog, dmBRCA2. These experiments revealed interaction between dmBRCA2 and dmPds5, an APRIN homolog. dmBRCA2 interacts strongly with hAPRIN, Rad51 and FANCD2, but weakly with hPDS5A. The study of potential interactions between hBRCA2 and hPDS5A was not pursued, for reasons that are not clear. Endogenous hAPRIN interacts with endogenous hBRCA2 following IR exposure. Co-IP experiments using fragments of BRCA2 allowed the interaction domain on BRCA2 for APRIN to be mapped to BRC1, a region that also binds Rad51. Certain cancerassociated point mutations in BRCA2 BRC1 exhibit reduced interaction with APRIN and/or with Rad51. A proportion of these were tested for their ability to rescue I-SceI-induced HR in the context of full-length BRCA2, when transiently expressed in BRCA2 mutant DLD1 cells and rescue of HR showed some correlation with APRIN binding. However, not all mutants were studied. siRNAmediated depletion of APRIN sensitizes 293T cells to IR and MMC and reduces Rad51 focus formation. A transiently expressed, I-SceI-activated HR reporter yielded fewer HR products in cells depleted of APRIN. Why the authors used this poorly controlled, transient HR system is not clear. A semi-quantitative ChIP assay suggests that APRIN accumulates near I-SceI-induced DSBs, but nuclear focus formation by APRIN in response to IR was not reported. Following release of cells from aphidicolin, APRIN co-IPs with BRCA2 only at the 4 hour time-point, but not at the 6 hour time-point, and this interaction is abolished by Atm inhibitors. APRIN IP's at the 4 hour time-point contain certain replication factors including PCNA, suggesting that it might promote interaction of BRCA2 with replication factors in response to replication stress. The authors examine APRIN levels in breast cancer, and report that low levels of APRIN correlate with improved survival in ER negative breast cancer.
Comments: This account of a new BRCA2-associated protein is weakened by the use of unconvincing repair assays. The BRC1 HR rescue experiments in DLD1 BRCA2 mutant cells are weak, since they are based upon a transient HR reporter expression system and were apparently not corrected for transfection efficiency. Similarly, the use of transient transfection of HR reporters in 293T cells is likely to introduce significant experimental error, especially since it involves sequential transfections (siRNA followed by DR-GFP). It would be more convincing if the authors were to work with characterized cell lines carrying single copy integrants of HR reporters, correcting for transfection efficiency etc. The use of 293T cells to study sensitivity to DNA damaging agents and chromosome breakage is not ideal, and the survival assays are not clonogenic. Rather, acute cell death is measured at 48 hours post-damage. The use of clonogenic assays in primary MEFs or primary human fibroblasts is more rigorous. Indeed, it is not clear how to interpret the 293T transient survival assays. The chromosome breakage in 293T cells is not quantified and, again, 293T are not the cell line of choice for this type of assay. The ChIP assay is at best semi-quantitative. Does APRIN normally accumulate at Rad51/BRCA2 IR-induced foci? Although I think that the authors have shown that APRIN does interact with BRCA2 under certain DNA damage/replication stress conditions, the m/s is weakened by repeated use of weak functional assays.
Referee #3 (Remarks to the Author):
This manuscript reports on identification of APRIN as a BRCA2-interacting and cohesion related human protein that is part of the DNA damage response machinery, and whose aberrantly lower levels or loss in clinal cancer specimens correlates with good response to anthracycline based chemotherapy. The mechanistic aspccts of APRIN's involvement in the BRCA2 pathway of DNA repair are supported by the demonstration that APRIN becomes recruited to sites of DNA double strand breaks, that its presence in the BRCA2 complexes facilitates complex formation of BRCA2 with additional DDR /replication proteins, that the APRIN-BRCA2 interaction is induced by DNA damage, APRIN expression is a prerequisite for proper localisation of Rad51 and BRCA2 in nuclear DNA damage foci, and for resistance of mammalian cells to several genotoxic insults. Furthermore, the authors exploited the BRCA2 mutation database and showed that several of the so-far functionally uncharacterized subtle mutations of BRCA2 found associated with breast cancer specifically disable the physical interaction between APRIN and BRCA2. Overall, these results are largely novel, inspiring and of interest to a wide audience of researchers in several fields, including cell cycle and DNA damage response, tumorigenesis, and personalized treament. The experiments are well controled and the conclusions mostly well supported, with a few reservartions listed below. It is also evident that this study required multiple complementary approaches and together with the clinical part the entire dataset represents a considerable amount of work. Therefore, in my opinion this manuscript clearly deserves to be considered for publication and, if improved in some of the less convincingly documented parts (see below), it should significantly boost the knowledge in the mentioned fields.
Critical comments and suggestions 1. One important point that needs more clarification is the potential role of APRIN in nuclear transport of Rad51 and BRCA2, rather than just their recruitment to sites of damage. The authors report that in the absence of APRIN, there was less nuclear Rad51 and BRCA2, but is is unclear whether this reflects mainly the protein instability (increased turnover) of these repair proteins (possibly due to the lack of the more stable complexes), or APRIN being involved in nuclear import or prevention of nuclear export of Rad51/BRCA2. 2. The evidence for APRIN being required for multiple relevant interactions, such as with PCNA, PALB2, CDC45, RAD21...is solid, however it is unclear to what extent are these interactions direct or a surrogate for a larger multiprotein complex. 3. The documented impact of the chemical ATM inhibitor on the observed phenotype is very useful, however the fact that APRIN was previously suggested to be a substrate of ATM/ATR (which is a good argument for its relevance in the global cellular response to DNA damage) could be exploited better. Ideally, one would like to see the ATM target site mutated and the nonproshorylatable mutant APRIN tested for at least some of the observed phenotypes (e.g. interactions with BRCA2 and Rad51, recruitment to DSBs and sensitivity to genotoxic insults). This analysis, if conclusive, would greatly enhance the value of the manuscript. On the other hand, if the other critical points could be solved, the role of the ATM phosphorylation site might be pursued in a follow-up study, and the manuscript would be sufficiently convincing and represent sufficient advance to warrant publication in te Journal. 4. A major prediction from authors' conclusions would be that cells lacking APRIN should also become sensitive to PARP inhibitors. This should be tested to support the notion of APRIN being involved in homologous recombination and having impact on response to treatment. 5. The authors speculate that the loss of APRIN in subsets of cancer specimens might reflect promoter hypermethylation. This is plausible and the authors might like to mine the available expression array data to discuss whether the levels of APRIN mRNA are also lower in the cases (at least a subset of them) that have been assessed by immunohistochemistry. This would help to argue that the defect is at the transcript, rather than protein level. Of course if there was a direct evidence for promoter methylation, that would be even better. 6. In Figure 3 , the survival data would be more informative if also the clinically relevant dose of 2Gy was used, along with the higher doses shown in the figure. 7. In Figure 4A , it is very difficult to see the Rad51 foci and hence judge the data, however this may just be a technical problem with the proper dispaly of the images on this referee's computer. Response: We are pleased that the reviewer finds our study interesting. has the same GFP level than A1109V that still interacts with APRIN.
Response: As the reviewer points out both S1069F and A1109V BRCA2 mutations impair the APRIN-BRCA2 interaction but to differing degrees (as shown by the IP/western blot experiment in Figure 2D ). In addition, both mutants impair HR as assessed by the DR-GFP assay ( Figure 2E ). We believe the lack of absolute correlation between the level at which the BRCA2/APRIN interaction is abrogated and the level of HR impairment can be explained by a threshold effect.
It is likely that either complete ablation or a modest impairment of the BRCA2-APRIN interaction caused by a single amino acid alteration could have similar effects on HR efficiency (a 40% reduction in HR frequency). This scenario would be unlike a complete loss of the BRCA2 C-terminus, as seen for mutations such as c.6174delT, which have a much more severe effect on HR ( Figure 2E ).
We have modified the text accordingly to clarify this (on p8).
" The lack of correlation between the strength of loss of interaction ( Figure 2D ) and the impairment on HR ( Figure 2E ) seen for variant S1069F when compared to A1109V and M1149V may be explained by a threshold effect. It may be possible that either complete ablation of or a modest impairment of the BRCA2-APRIN interaction caused by a single amino acid alteration could have similar effects on HR efficiency. This scenario is unlike a complete loss of the BRCA2 C-terminus, as seen for mutations such as c.6174delT, which has a much more severe effect on HR efficiency ( Figure 2E )."
It is not clear why the authors do not measure HR with the T1011R mutant, which is the most impaired mutant for interaction with APRIN.
Response: The T1011R mutation is within the BRC1 domain. We and others have shown that this alteration impairs binding of BRCA2 to RAD51 ( Figure 2D and (Tal A, Arbel-Goren R, and Stavans J. J Mol Biol (2009), 393(5): 1007-1012)). The reason why we did not include this mutant in further studies is that any impairment caused by the T1011R mutation could be explained by a change in BRC structure/function and loss of the BRCA2-RAD51 association, rather than the BRCA2-APRIN interaction. Mutants Q1073R, N1101Y, A1109V, M1149V and S1069F lie outside of the BRC repeat but within the APRIN binding region of BRCA2 (illustrated in Figure 2A ) and therefore any effects seen on HR were likely independent of the RAD51 binding effect and could be ascribed to a change in the BRCA2-APRIN interaction.
It is not clear what is the explanation for the increase of GFP positive cells (using the N1101Y mutant).
Response: Although the N1101Y variant appears to have no effect on the BRCA2-APRIN interaction, we cannot rule out the possibility that this mutation has an enhancing effect on HR. It is feasible that this mutation modulates the interaction of BRCA2 with other binding partners and it is these additional interactions that modulate HR. 
Response:
We agree that at 8 and 10 Gray we see a modest reduction in survival in the BRCA2 siRNA transfected cells compared to those transfected with siCON. However, taking the entire dose-response data into account, it seems reasonable to conclude that APRIN silencing sensitizes to IR. To strengthen the basis of this conclusion we now performed IR survival assays in an additional tumour cell line, Hela, where the IR dose range is more representative of clinically-used exposure (1-4 Gray, new Figure 3D ). This new data clearly demonstrates IR sensitivity caused by APRIN siRNA. As the reviewer suggested we have also provided new images for DAPI and RAD51 confocal imaging in Figure 4A . Response: As the referee suggests, transfection efficiency could be a mitigating factor here, especially as these experiments involved co-transfection of siRNA as well as HR reporter plasmids. Given these issues, we repeated these experiments using a cell line carrying a single copy DR-GFP cassette. These new experiments (new Figure 4C with accompanying western blots in Figure 4B Response: The reviewer is slightly mistaken in the claim that we measured cell death 48 hours post-damage. We did in fact measure cell viability 5-7 days following the introduction of the DNA damaging agent. We have now added sensitivity curves to IR (improved Figure 3D ) and PARP inhibitor (new Figure   3E ), which were performed by colony formation assay on APRIN and BRCA2 Response: In the manuscript we showed that silencing of APRIN affects nuclear localization of RAD51 and BRCA2 ( Figure 4B and S4E). To address this further we have also demonstrated that APRIN silencing reduces RAD51 ( Figure 4A) and BRCA2 nuclear foci (new Figure S4C/D) . We can only speculate that APRIN may be involved in the nuclear retention of BRCA2 and RAD51 at DSBs, however we cannot exclude additional mechanisms such as protein turnover. As yet it is not completely clear how BRCA2 and RAD51 turnover occurs, but potentially this could be investigated. However, we do believe this is a much larger study looking at the fine control of these important HR proteins.
2.
The evidence for APRIN being required for multiple relevant interactions, such as with PCNA, PALB2, CDC45, RAD21...is solid, however it is unclear to what extent are these interactions direct or a surrogate for a larger multiprotein complex.
Response: We agree that we cannot discriminate between APRIN being the direct physical link between BRCA2 and PCNA, PALB2, CDC45 and RAD21.
Although, since siRNA silencing APRIN ablates the interaction between BRCA2
and PCNA, CDC45 and RAD21 we can conclude that APRIN is required for these interactions ( Figure 6C ). The definitive experiment here would involve structural analysis of these interacting proteins as a complex, which we believe is outside the scope of this study. We found however that these demonstrated no effect on the APRIN/BRCA2 interaction (data not shown). It does seem possible that there are other potential ATM phosphorylation sites on APRIN that modulate the BRCA2/APRIN interaction. We believe however that this would benefit from being included as a subsequent independent study due to the numerous potential sites that could be investigated.
4.
A major prediction from authors' conclusions would be that cells lacking APRIN should also become sensitive to PARP inhibitors. This should be tested to support the notion of APRIN being involved in homologous recombination and having impact on response to treatment.
Response:
We have now conducted the experiment suggested and find that Hela cells, transfected with either BRCA2 or APRIN siRNA exhibited increased sensitivity to a clinical PARP inhibitor, olaparib (new Figure 3E) , an observation consistent with a role for APRIN in modulating HR.
5.
The authors speculate that the loss of APRIN in subsets of cancer specimens might reflect promoter hypermethylation. This is plausible and the authors might like to mine the available expression array data to discuss whether the levels of APRIN mRNA are also lower in the cases (at least a subset of them) that have been assessed by immunohistochemistry.
This would help to argue that the defect is at the transcript, rather than protein level. Of course if there was a direct evidence for promoter methylation, that would be even better.
Response:
We agree that some evidence of APRIN promoter methylation would support a notion that APRIN deficiency could be detected at the transcript level.
To address this we have examined APRIN promoter methylation by methylation specific PCR (MSP) on a panel of bisulphate treated genomic DNA from basallike breast cancer cell lines. We examined 6 CpG islands and show in the revised manuscript that a number of these islands have enhanced methylation. In addition we show that the degree of methylation correlates with APRIN expression as assessed by qRT-PCR (new Figure 7D-F) 6. In Figure 3 , the survival data would be more informative if also the clinically relevant dose of 2Gy was used, along with the higher doses shown in the figure.
Response: In our revised manuscript we have now included sensitivity curves to IR (revised Figure 3D ), which were performed by colony formation assay in APRIN and BRCA2 silenced Hela cells including clinically relevant doses of 1 and 2 Grays. These results further support the role for APRIN in the repair of DNA damage.
7.
In Figure 4A , it is very difficult to see the Rad51 foci and hence judge the data, however this may just be a technical problem with the proper dispaly of the images on this referee's computer.
Response: To make these images easier to interpret we have now provided separate panels for DAPI and RAD51 confocal images, as well as the merged image, in Figure 4A . 
EMBOJ -This email has been sent through the NPG Manuscript Tracking
System NY-610A-NPG&MTS Thank you for submitting your revised manuscript on the APRIN-BRCA2 interaction for our consideration. We have now received the feedback from two of the original referees (please see their comments copied below) and I am happy to inform you that they now consider the manuscript in principle suited for publication in The EMBO Journal, pending clarification of a few specific scientific points; I therefore would like to invite you to address these remaining concerns of referee 1 in a final round of re-revision.
In addition, there are a number of editorial issues that will need to be addressed before we should be able to accept the manuscript: 1) Figures & Image Quality: -all TIFF figure files you uploaded are very pixelated and of too low resolution for publication purposes. Please try to generate files of higher resolution and carefully review them before uploading -also the figures in the supplementary information PDF suffer from the same resolution problem and should be improved -while some of the darkest immunoblot panels have been improved, various others still suffer from too little contrast between signals and background -please upload a single individual file for Figure 7 rather than two parts 2) Please amend the manuscript text (next to the Acknowledgement section) with an Author Contribution statement and a Conflict of Interest declaration 3) extensive parts of the Material & Methods section appear to have been taken over as nearly verbatim copies from the cited manuscript by DS Tan et al (Breast Cancer Research and Treatment 2008) . This relates to the sub-sections 'Invasive breast cancer tissue microarray', 'Immunohistochemical assay', and 'Statistical Analysis'. Although I understand that these issues concern only the Material & Methods section and passages taken from your (or your co-authors') own original works, the degree and extent of textual identity here will necessitate a certain amount of rewriting and modifications so as to avoid possible allegations of self-plagiarism following publication in the present form. I hope you appreciate that this will be in your own best interest. 4) We now encourage the publication of source data, particularly for electrophoretic gels and blots, with the aim of making primary data more accessible and transparent to the reader. I am taking this opportunity to ask you if you would be willing to provide a single PDF/JPG/GIF file per figure comprising the original, uncropped and unprocessed scans of all gel/blot panels used in the respective figures. These should be labelled with the appropriate figure/panel number, and should have molecular weight markers; further annotation would clearly be useful but is not essential. A ZIP archive containing these individual files can be uploaded upon resubmission selecting " Figure  Source Data" as object type , and would be published online with the article as a supplementary "Source Data" file.
I am therefore returning the manuscript to you once more, kindly asking you to address the remaining scientific and editorial points and to get a re-revised version back to us as soon as possible; following these revisions we should then hopefully be able to swiftly proceed with acceptance and publication of the paper. Please do not hesitate to get back to me should you require any further clarifications in this regard.
Yours sincerely,
Editor
The EMBO Journal
Instructions for preparing your revised manuscript:
Please check that the title and abstract of the manuscript are brief, yet explicit, even to nonspecialists.
Please remember: Digital image enhancement is acceptable practice, as long as it accurately represents the original data and conforms to community standards. If a figure has been subjected to significant electronic manipulation, this must be noted in the figure legend or in the 'Materials and Methods' section. The editors reserve the right to request original versions of figures and the original images that were used to assemble the figure.
-
Referee #1 (Remarks to the Author):
This resubmission by Brough et al. has mostly adressed the issues raised in the previous review. The following points still need to be resolved. Please find attached the revised version of our manuscript. Where possible we have tried to increase the resolution of the main and supplementary figures as well as rewriting many parts of the main text on your instructions. Please do let us know if there are additional changes you wish us to make. Below we have also included a point by point response to the referee's comments. As you will see, although the suggestion of additional foci experiments could be interesting, the practical aspects of obtaining APRIN and BRCA2 foci somewhat preclude an in depth analysis as suggested. Nevertheless we do provide a considerable amount of other data (for example western blot data) that supports the central findings of the paper. request that we assess co-localisation between RAD51/BRCA2 and APRIN; from the previous review, Referee 1's comment was, "Does siRNA against APRIN has an effect on BRCA2 foci formation after DNA damage? Do BRCA2 or RAD51 colocalize with APRIN after DNA damage?". As we stated in our previous response, although, like BRCA2, APRIN does not seem to form very discrete foci (as opposed to RAD51), we do observe instances where APRIN co-localises with RAD51 ( Figure S4A ), and BRCA2
( Figure S4B ). In the discussion of the revised manuscript, we do highlight this issue, for example:
"Previously it has been shown that BRCA2 forms S-phase nuclear foci that co-localise with other repair molecules following DNA damage (Wong et al, 1997) , Using a MYCtagged APRIN expression construct we show that APRIN also forms nuclear foci that occasionally co-localise with RAD51 ( Figure S4A ) and BRCA2 ( Figure S4B ). Admittedly these co-localisations were not as frequent nor as convincing as the RAD51 and BRCA2 association, for example, however we believe this to be due to the additional non-repair 
Response:
We agree that at 8 and 10 Gray we see a modest reduction in survival in the BRCA2 siRNA transfected cells compared to those transfected with siCON (65 % vs. 58 % Surviving fraction at 10Gy respectively). However, taking the entire dose-response data into account, and also the results in other cell line models it seems reasonable to conclude that APRIN silencing sensitizes to IR.
Minor comment: Figure 3A : The siAPRIN-3 curve do not correlate with the dots for Aphidicolin treatment.
We have used a four parameter logistical regression to fit curves to the survival data, as this best suited the majority of the data. Although we could fit the siAPRIN-3 curve with a different form of regression, we feel that it would be not a fair test to use different regression models for different data sets. Nevertheless, at best, the regression we use slightly underestimates the aphidicolin sensitivity of siAPRIN-3 transfected cells, rather than overestimating it.
The authors have adequately responded to my comments and in my opinion, the revised manuscript now can be recommended for publication
Additional Correspondence 03 November 2011
Thank you for submitting your re-revised manuscript (EMBOJ-2011-77875) to The EMBO Journal. On conducting our routine pre-acceptance figure quality checks, we noticed irregularities (such as background discontinuities) in several panels with immunoblot data (e.g. in Fig. 6 B and C, or Fig. 1 B and E). According to our editorial policies, I therefore need to ask you to kindly provide us with the original scans for all blots used in Figures 1 and 6 , including sufficient labeling and explanation of how blots were probed and which parts were put together in which way to assemble the final figure. Please send us these data, ideally as ZIP format email attachment (or if necessary via an FTP download server), as soon as possible, in order to allow us to swiftly proceed with the assessment and eventual publication of the study. Should you have any questions in this regard, please do not hesitate to get back to me directly. Thank you.
Editor
Additional Correspondence 13 December 2011
Many thanks for your email and again apologies for the confusion caused.
To clarify the whole situation we have, as you have suggested, reconstructed Fig 1 B , D, E and Fig 6 B, C from the original scans (also attached again in the email to follow). In each case this has removed the previous manipulation errors as well as some of the pixilation effects. In each case we have simply copied over images from the scan TIF images without any manipulation or re-sizing. Importantly, none of the results/conclusions are changed.
For Fig 1B we have now reassembled this panel without any re-sizing, including the HA WCL blot that now matches the scan.
For Fig 1D, in the previous version we submitted a version of the APRIN and MYC WCL panels that were re-sized. We now include non-resized images from the scans. For the BRCA2 WCL the new image should have none of the resolution problems as before. We can confirm that the images are from the same gel/exposure.
For Fig 1E we have now removed the image processing artefacts and introduced separation between lanes that were non adjacent on the original blot. For lanes 3-6 in the APRIN row we previously sent you a scan from a different exposure to the figure as you suspected as we thought this was a better image. We have resolved this and the scans and figures now directly match.
For Fig 6B we incorrectly sized RAD21 on the figure as approximately 75kDa. The predicted size (from the primary amino acid sequence) of RAD21 is approximately 75kDa, but it is well established that the endogenous protein runs at > 100kDa, as now shown in the scan and the figure.
As you point out, there is a cut line beneath the lower RAD21 band -originally we cut this blot here to enable different antibody probing on different parts of the blot. For the RAD21 immuno detection we put the blot back together. However, as the lower portion of the blot does not actually include RAD21, for clarity we now only show the top portion of the blot.
For Fig 6C we've again matched directly scan and figure. The vertical line in the BRCA2 WCL image is sellotape (used to stick the autorad into a lab book!) We've now removed the tape and rescanned.
